BioRestorative Therapies, Inc. (BRTX): Form 8-K filed 2026-09-02
- Accepted by EDGAR
- 2026-09-01 18:09 ET
- Event date
- 2026-08-26
- Accession no.
- 0001213900-26-096337
- Original filing
- SEC EDGAR filing index
Items reported
- Item 4.01: Changes in Registrant's Certifying Accountant
The company's independent auditor resigned, declined to stand for re-appointment or was dismissed, or a new auditor was engaged. The company must disclose any disagreements or reportable events. - Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
A director or a named officer (such as the CEO or CFO) left or was appointed, or certain executive compensation arrangements were adopted or changed. - Item 9.01: Financial Statements and Exhibits
Lists the financial statements, pro forma information and exhibits filed with the report. It almost always accompanies another Item and is rarely news on its own.
Documents
| Type | Description | Document |
|---|---|---|
| 8-K | CURRENT REPORT | ea0304309-8k_biore.htm |
| EX-10.1 | CONSULTING AGREEMENT, DATED AS OF AUGUST 27, 2026, BETWEEN THE COMPANY AND CURRE | ea030430901ex10-1.htm |
| EX-10.2 | CFO CONSULTING AGREEMENT, DATED AS OF AUGUST 27, 2026, BETWEEN THE COMPANY AND B | ea030430901ex10-2.htm |
| EX-10.3 | CONSULTING AGREEMENT, DATED AS OF AUGUST 27, 2026, BETWEEN THE COMPANY AND EEAK | ea030430901ex10-3.htm |
| EX-10.4 | FORM OF INDEMNIFICATION AGREEMENT | ea030430901ex10-4.htm |
This page lists what the filing reports; it does not summarize or interpret it. Read the original documents on SEC EDGAR. How to read an 8-K.